Stockscreener 앱 받기
1.68
0.60%
0.01
시간 외 거래:
1.66
-0.02
-1.19%
전일 마감가:
$1.67
열려 있는:
$1.68
하루 거래량:
675.95K
Relative Volume:
0.65
시가총액:
$221.81M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-3.4132
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+1.20%
1개월 성능:
-2.89%
6개월 성능:
+5.66%
1년 성능:
-3.45%
1일 변동 폭
$1.66
$1.73
1주일 범위
$1.6372
$1.73
52주 변동 폭
$1.33
$2.26
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.68 | 220.49M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics (IKT) Consolidates Near $1.67 – Key Levels in FocusGolden Cross - newsline.com
IKT Initiates Coverage On Oppenheimer -- Rating Set to Outperfor - GuruFocus
Oppenheimer Initiates Inhibikase Therapeutics at Outperform - marketscreener.com
Inhibikase Therapeutics (IKT) Tests Support Zone After Slight DeclineFibonacci Entry Signals - newsline.com
IKT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Recovery Stocks - newsline.com
IKT Technical Analysis | Trend, Signals & Chart Patterns | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics (IKT) Narrows Lower: Testing Key Support Near $1.61Size Factor - newsline.com
IKT Q1 2026 Earnings: Narrow EPS Beat as Clinical Pipeline Progress ContinuesSegment Revenue Breakdown - newsline.com
Inhibikase Therapeutics (IKT) Holds Near Support Amid Biotech Sector HeadwindsBear Pennant - newsline.com
Inhibikase Therapeutics (IKT) Recovers 3.5% as Buyers Defend Key Support LevelMAMA Signal - The Legal Advocate
Inhibikase Therapeutics (IKT) Holds Near Support Amid Narrow Trading RangeScalping Stock Signals - The Legal Advocate
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inhibikase Therapeutics (IKT) Dips 2.87% as Stock Approaches Critical Support at $1.61Buyback Factor - newsline.com
Inhibikase Therapeutics (IKT) Faces Selling Pressure as Stock Retreats to $1.69Parabolic SAR - Newser
Inhibikase Therapeutics (IKT) Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Takes Center StageShared Momentum Picks - Newser
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibikase Gains EU Clearance for Global PAH Trial - MyChesCo
Inhibikase Therapeutics, Inc. (IKT) Competitors - Meyka
IKT Stock Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 By Investing.com - Investing.com Nigeria
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 - Investing.com India
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT) - The Globe and Mail
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors - TipRanks
Is Inhibikase Therapeutics (IKT) Fairly Valued After Q1 2026 EPS - GuruFocus
Inhibikase Advances PAH Drug with Global Phase 3 Trial Launch - BriefGlance
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum - ChartMill
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase (NASDAQ: IKT) deepens Q1 loss as pivotal PAH trial advances globally - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INHIBIKASE THERAPEUTICS ($IKT) Releases Q1 2026 Earnings - Quiver Quantitative
Inhibikase (NASDAQ: IKT) advances IMPROVE-PAH as Q1 2026 loss widens - Stock Titan
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension - TipRanks
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
What XXxs fundamentals reveal about its future (Rallies) 2026-05-08AI Powered Stock Picks - Newser
Inhibikase Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - newser.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Quarterly Profit Report - newsline.com
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):